Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vasodip-Combo 20
- Development stage
- Discontinued
- Lead developer
- Dexcel Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vasodip-Combo 20 is a fixed-dose combination antihypertensive medication containing the calcium channel blocker lercanidipine hydrochloride (10 mg) and the ACE inhibitor enalapril maleate (20 mg). Lercanidipine is a dihydropyridine that blocks L-type calcium channels in vascular smooth muscle cells, causing peripheral vasodilation and reducing systemic vascular resistance. Enalapril, a prodrug of enalaprilat, inhibits the angiotensin-converting enzyme, thereby reducing the production of angiotensin II and aldosterone, which further lowers blood pressure. This combination is indicated for essential hypertension, particularly in patients whose blood pressure is not sufficiently controlled by enalapril monotherapy. Meir Medical Center sponsored a Phase 4 clinical trial (NCT01211314) to evaluate the drug's efficacy and safety using 24-hour ambulatory blood pressure monitoring.
- Brand names
- Vasodip-Combo 20Vasodip-Combo20Vasodip-Combo-20
- Other names
- lercanidipine + enalaprilenalapril + lercanidipinelercanidipine hydrochloride + enalapril maleateLercanidipine/enalapril fixed combination
02
Targets
ACE (Angiotensin Converting Enzyme)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on Vasodip-Combo 20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vasodip-Combo 20.